MOHAP Import Permits UAE: A Complete 2026 Guide for UK Pharmaceutical Exporters

The United Arab Emirates is one of the highest value pharmaceutical markets in the Middle East, with a regulatory environment that is sophisticated, well documented, and at the same time genuinely complex because of the federal structure. UK exporters and Saudi or African importers using the UAE as a hub frequently underestimate one specific feature of the system: pharmaceutical regulation in the UAE is administered at three levels. The federal Ministry of Health and Prevention (MOHAP) holds the primary jurisdiction. Two emirate level authorities, the Dubai Health Authority (DHA) and the Department of Health Abu Dhabi (DOH), regulate within their emirates. Each of the three has its own remit, its own e-systems, and its own day to day touchpoints.

This guide is written for UK pharmaceutical exporters, MHRA-licensed wholesalers, and UAE based hospital procurement teams who need a single, practical reference for the 2026 import permit and registration process. It covers the regulator structure, the four practical routes into the UAE market, the documentation pack, free zone versus mainland implications, the MOHAP e-system enhancements rolled out through 2025 and 2026, hospital procurement networks, cold chain logistics from Heathrow to Dubai and Abu Dhabi, common pitfalls, and how Euro Biom supports the supply.

UAE Pharmaceutical Market Context

The UAE pharmaceutical market is shaped by three structural features that together create a distinctive demand profile. First, the population is one of the most expatriate weighted in the world, with roughly 88 percent of residents from outside the Emirates. This produces broad formulary diversity, with hospitals routinely procuring medicines preferred by Emirati nationals alongside European, North American, South Asian, Filipino and African market preferences. Second, the UAE operates a high specification hospital network anchored by international systems including Cleveland Clinic Abu Dhabi, Mediclinic Middle East, NMC Healthcare, American Hospital Dubai, Saudi German Hospital, and the Dubai Health Authority public network including Rashid Hospital and Latifa Hospital, alongside the SEHA Abu Dhabi public network covering Sheikh Khalifa Medical City, Tawam, Mafraq and Al Ain. Third, Dubai serves as a regional logistics and re export hub, with JAFZA and DAFZA enabling pharmaceutical distribution throughout the GCC, Africa, and South Asia from a UAE base.

For UK exporters, all three features matter. The expat formulary diversity creates ongoing demand for specialty, named patient, and shortage supply that is precisely the segment where MHRA-licensed UK suppliers add most value. The high specification hospital network sets quality expectations that align well with UK GDP and MHRA standards. The free zone hub creates additional commercial routes for UK exporters whose UAE work is not solely UAE local supply but includes regional re export through DXB or Jebel Ali Port.

For more on the UAE specifically, see our UK pharmaceutical exporter to UAE landing page, and for regional context see the UK pharmaceutical exporter to GCC overview.

MOHAP Structure

The Ministry of Health and Prevention is the federal authority responsible for healthcare policy, hospital regulation, public health, and pharmaceutical regulation across the UAE. Within MOHAP, the entity that most matters for pharmaceutical exporters is the Drug Department (sometimes referred to as the Drug Sector or the Pharmaceutical Department, depending on the document version). The Drug Department holds these primary responsibilities:

• Registration of pharmaceutical products for the UAE local market
• Licensing of pharmaceutical companies operating in the UAE (manufacturers, importers, wholesalers, scientific offices)
• Issuance of shipment specific import permits where products are intended for UAE local consumption
• Pharmacovigilance and post marketing surveillance
• Inspection of UAE based pharmaceutical companies for compliance with GDP and the UAE pharmaceutical practice rules
• Pricing review for branded prescription medicines (UAE operates a published price referencing system)
• Coordination with the Gulf Health Council for the GCC Centralised Registration pathway

MOHAP does not directly regulate hospital pharmacy practice within Dubai or Abu Dhabi, where DHA and DOH carry the day to day touchpoint with hospitals. However, every imported medicine that is intended for the UAE local market must be registered through MOHAP, regardless of which emirate it is consumed in.

The Three Tier UAE Regulator System

For UK exporters, the practical question is rarely "which regulator owns the system?" but "which regulator do I deal with for this specific consignment?" The answer depends on the destination of the goods and the kind of activity involved.

MOHAP (federal)

Applies to: marketing authorisation registration, federal pharmaceutical company licensing, mainland import permits where the consignment crosses MOHAP-controlled customs entry points, pricing approvals, and pharmacovigilance. UK exporters supplying registered products into the broad UAE market via a mainland local agent encounter MOHAP as the primary regulator.

DHA (Dubai)

Applies to: pharmaceutical practice within the Emirate of Dubai outside the DHCC zone, including pharmacy licensing, hospital pharmacy operations, and DHA hospital procurement (Rashid Hospital, Latifa Hospital, Dubai Hospital, the broader DHA network, and DHA-affiliated private facilities). DHA also operates the special import pathway for unregistered medicines used by Dubai hospitals for named patient cases. UK exporters supplying unregistered medicines to Dubai hospitals on a named patient basis typically interact with DHA through the receiving hospital pharmacy.

DOH (Abu Dhabi)

Applies to: pharmaceutical practice within the Emirate of Abu Dhabi, including the SEHA public hospital network (Sheikh Khalifa Medical City, Tawam, Mafraq, Cleveland Clinic Abu Dhabi as a SEHA partner, Al Ain hospitals), licensed private facilities (Mediclinic Middle East, NMC, Burjeel), and pharmacy regulation across the emirate. DOH operates a special import procedure broadly equivalent to the DHA process. UK exporters supplying unregistered medicines to Abu Dhabi hospitals interact with DOH through the receiving hospital pharmacy.

DHCR (Dubai Healthcare City)

Applies to: clinical operations within the Dubai Healthcare City free zone. DHCC has its own regulatory framework administered by the Dubai Healthcare City Regulatory authority. Hospitals and clinics operating within DHCC, including American Hospital Dubai's DHCC clinic, Mediclinic City Hospital, and other DHCC affiliated facilities, are regulated under DHCR rather than DHA in some respects, although there is increasing coordination between the two.

The takeaway for UK exporters is straightforward: the three regulators do not duplicate each other, they cover different surfaces. A UK consignment of a registered product going to a private retail pharmacy in Dubai mainland will pass under MOHAP customs and be retailed under DHA pharmacy rules. A UK named patient shipment to Cleveland Clinic Abu Dhabi will be authorised by DOH under its special import process. A UK consignment of unregistered medicine to American Hospital Dubai's DHCC clinic may go under DHA and DHCR oversight depending on the clinical setup. Working with a knowledgeable UAE local agent or hospital pharmacy team early in the process is the simplest way to identify the right regulator pathway for a specific shipment.

Four Routes into the UAE Market

UK pharmaceutical exporters typically encounter one of four pathways depending on the product, the customer, and the urgency.

1. Full MOHAP Registration

Required for products that will be supplied at scale into the UAE market on a routine basis through retail pharmacy or hospital tender channels. The marketing authorisation holder appoints an MOHAP-registered local agent, who submits the registration dossier through the MOHAP e-system. The dossier follows the GCC eCTD format with UAE specific national supplements. Registration is granted as a renewable authorisation, typically valid for five years, subject to variation submissions and pricing review.

Full registration is the prerequisite for retail pharmacy stocking, registered hospital tender lists, and onward private insurance reimbursement under DHA Daman, Thiqa, and other UAE health insurance schemes.

2. Named Patient and Special Import (DHA / DOH)

The DHA Special Import procedure and the DOH equivalent provide a regulated pathway for unregistered medicines required for individual patients in Dubai or Abu Dhabi hospitals. The application is initiated by the receiving hospital pharmacy, with documentation provided by the UK supplier, including an MHRA Certificate of Pharmaceutical Product, batch CoA, batch release certificate, and GDP supply chain certification. Authorisation is shipment specific and is typically issued within 5 to 10 working days for non urgent cases and within 48 to 96 hours for urgent or life threatening cases.

This is the standard route for rare disease therapies, specialty oncology agents not yet MOHAP registered, gene and cell therapies, paediatric formulations, and named patient compassionate use cases. UK exporters with MHRA Wholesale Dealer Authorisation map cleanly onto this process because the UK Regulation 167 framework and the MHRA Special Import Licence are familiar to UAE hospital regulators. See our named patient supply service for the UK side process.

3. Free Zone Distribution (JAFZA, DAFZA, DHCC)

UAE free zones provide a different regulatory perimeter that UK exporters can use for non UAE local consumption activity. Jebel Ali Free Zone (JAFZA) and Dubai Airport Free Zone (DAFZA) operate as bonded logistics zones with simplified regulatory rules for goods that are not entering the UAE local market. Pharmaceutical distributors operating from JAFZA or DAFZA can hold and re export inventory to other GCC states, Africa, South Asia, and beyond without full MOHAP registration of every product, provided the goods are not consumed in the UAE.

Dubai Healthcare City (DHCC) is structured differently, as a clinical free zone with its own DHCR regulatory authority covering hospital and clinic operations. Pharmaceutical activity within DHCC for clinical use in DHCC hospitals follows the DHCR framework alongside DHA in most cases.

UK exporters using the UAE as a regional hub commonly partner with a JAFZA or DAFZA based pharmaceutical distributor for onward distribution into Saudi Arabia, Oman, Kuwait, and African markets. The UK consignment is shipped to Heathrow, then to DXB and into the free zone bonded warehouse, with onward shipment under the destination market's import procedures.

4. Hospital Direct via DHA-Licensed Importer

Large hospital systems in the UAE (SEHA, Cleveland Clinic Abu Dhabi, Mediclinic Middle East, NMC Healthcare, American Hospital Dubai, Saudi German Hospital) often hold their own pharmaceutical distribution licences or work through preferred DHA or DOH-licensed importers. This pathway combines aspects of MOHAP registered supply (for registered products) and DHA or DOH special import (for unregistered named patient cases) into a single hospital procurement relationship. UK exporters with established UAE hospital relationships typically operate primarily through this route, with the local agent or hospital licensed importer handling the regulatory paperwork for each shipment.

Documentation Required

The MOHAP and DHA documentation packs share most components with the SFDA dossier and other GCC regulators, with UAE specific additions for halal and alcohol disclosure, Arabic labelling, and free zone movement where applicable.

UAE specific points worth highlighting:

• Halal and alcohol disclosure is not a blanket halal certification requirement, but products containing porcine derived gelatin, bovine derived materials, alcohol excipients, or vaccines containing porcine trypsin must declare these clearly. Misdisclosure or omission can lead to registration delays. A clear declaration handled at dossier preparation stage is rarely a problem.
• Pricing letters are required because the UAE operates a price referencing system. MOHAP reviews the proposed UAE retail price against the prices of the same product in defined reference countries, including the UK, France, Germany, and selected GCC states. Misalignment with reference country pricing can extend the registration timeline.
• Arabic labelling for UAE follows MOHAP rules that overlap with but are not identical to SFDA labelling rules. UK exporters supplying both Saudi Arabia and the UAE typically maintain separate Arabic labelling packs for each market.

Free Zone vs Mainland

The single most common confusion among UK exporters new to the UAE is the difference between mainland and free zone regulatory perimeters. Getting this wrong can mean either over compliance (paying for full MOHAP registration when free zone movement was available) or under compliance (assuming free zone rules apply when the consignment is actually entering the UAE local market).

Mainland

Pharmaceutical activity in UAE mainland is fully regulated by MOHAP federally and by DHA or DOH at emirate level. Companies require an MOHAP issued pharmaceutical company licence; products require full registration; import permits are issued for each shipment; pricing is reviewed; pharmacovigilance applies. Retail pharmacies, hospital pharmacies (DHA, DOH, SEHA, private), and standard wholesale operations all sit on the mainland regulatory perimeter.

Jebel Ali Free Zone (JAFZA)

JAFZA is a logistics and re export free zone administered by Dubai Multi Commodities Centre and the Jebel Ali Free Zone Authority. Pharmaceutical companies can hold a free zone trading or distribution licence allowing storage and re export of pharmaceutical products through Jebel Ali Port and onward to GCC, Africa, and South Asia markets. As long as the goods do not enter UAE local consumption, full MOHAP product registration is not required, although the free zone facility itself must comply with GDP and storage standards.

Dubai Airport Free Zone (DAFZA)

DAFZA is the air cargo equivalent of JAFZA, located at Dubai International Airport (DXB) and administered by the DAFZA authority. UK exporters using DAFZA for re export can take advantage of the bonded warehouse facilities and direct DXB connectivity. Same regulatory perimeter as JAFZA in terms of free zone vs mainland.

Dubai Healthcare City (DHCC)

DHCC is a clinical free zone with its own regulator (DHCR). It is not a re export zone in the JAFZA sense; it hosts hospitals, clinics, and medical service providers that operate under the DHCR regulatory framework. Pharmaceutical supply into DHCC clinical facilities is treated as supply for local consumption within UAE, but with the DHCR overlay rather than purely DHA in some respects. UK exporters supplying DHCC hospitals typically operate through a UAE local agent who is familiar with both DHA and DHCR documentation.

Strategic point: many UK exporters operate a hybrid pathway, with full MOHAP registration for the products they intend to supply into UAE local consumption, alongside JAFZA or DAFZA partnerships for onward GCC and Africa distribution. The two are complementary rather than alternatives.

MOHAP e-System: 2026 Updates

MOHAP has invested substantially in the digital regulatory platform that underpins pharmaceutical company licensing, drug registration, import permits, and post marketing pharmacovigilance reporting. Through 2025 and into 2026, the system has rolled out a series of enhancements that materially shorten the operational timeline for UK exporters.

Key 2025 to 2026 enhancements include:

• End to end digital import permit issuance. Permit applications, supporting document upload, fee payment, and final permit issuance are now fully digital. Average turnaround for routine import permits has reduced from 10 to 14 working days under the previous system to 3 to 7 working days when documentation is complete.
• Integrated customs handshake. The MOHAP e-system now communicates directly with UAE Federal Customs and the Dubai Customs system, allowing import permits to flow electronically into the customs clearance process at DXB and AUH without manual paperwork submission. This reduces the gap between MOHAP permit issuance and customs release at port of entry.
• Real time application status tracking. Local agents and their UK supplier partners can monitor application status, deficiency requests, and reviewer comments in real time through the e-system. This replaces the previous email and phone based touchpoint and significantly reduces the lead time for resolving deficiency issues.
• Online pharmacovigilance submission. Adverse event reporting, periodic safety update reports, and risk management plan submissions are now made via the e-system rather than email or paper submission.
• Variation submission digital workflow. Type IA, IB, and II variations are now processed through the digital workflow with defined target turnaround times.
• Pricing module integration. Reference country pricing data is integrated into the registration submission, streamlining the pricing review.

For UK exporters, the practical implication is that UAE permits and registration applications now move significantly faster than they did in 2023 and earlier, provided the documentation pack is complete and clean at submission. Investment in dossier readiness review pre submission has a higher return than ever because deficiency cycles are shorter and the platform now records reviewer comments for audit, making documentation quality more visible.

Hospital Procurement Networks

The UAE hospital landscape is one of the most internationally branded in the region. UK exporters supplying named patient, specialty, oncology, and rare disease products encounter a number of major networks, each with its own procurement governance.

SEHA (Abu Dhabi Health Services Company)

SEHA is the public hospital network for the Emirate of Abu Dhabi, operating Sheikh Khalifa Medical City (SKMC), Tawam Hospital (Al Ain), Mafraq Hospital, and a number of other facilities. SEHA procurement runs central tenders across these facilities, with named patient and specialty supply handled through facility level pharmacy departments under DOH special import authorisation.

Cleveland Clinic Abu Dhabi

Cleveland Clinic Abu Dhabi operates as part of the Cleveland Clinic global network and is a SEHA managed facility. It is one of the highest specification tertiary centres in the region, with significant demand for specialty oncology, cardiology, gastroenterology, transplantation, and paediatric medicines. Named patient and special import supply is well established, with authorisations processed through DOH.

Dubai Health Authority (DHA) Network

DHA operates the public hospital network in the Emirate of Dubai, including Rashid Hospital, Latifa Hospital, Dubai Hospital, and Hatta Hospital. Procurement runs through DHA central tendering for routine products and through hospital pharmacy departments for named patient and specialty supply, with DHA special import procedures applied to unregistered medicines.

Mediclinic Middle East

Mediclinic operates a network of private hospitals across the UAE, including Mediclinic City Hospital (DHCC), Mediclinic Welcare Hospital, Mediclinic Parkview Hospital, Mediclinic Airport Road Hospital (Abu Dhabi), and others. Procurement is centralised at the Mediclinic Middle East corporate level for major contracts, with specialty and named patient supply handled at facility pharmacy level.

NMC Healthcare

NMC operates a large network of hospitals and medical centres across the UAE under various brands including NMC Royal Hospital, NMC Specialty Hospital, and others. Procurement combines central tenders and facility level supply, with specialty and named patient activity at facility level.

American Hospital Dubai

American Hospital Dubai is a JCI accredited tertiary hospital with a substantial specialty practice including oncology, cardiology, and complex surgical specialties. Pharmaceutical procurement combines registered product supply through licensed UAE distributors and named patient supply via DHA special import process.

Other Networks

Additional networks worth noting include Saudi German Hospital Group (Dubai and Sharjah operations), Burjeel Holdings (Abu Dhabi based with multiple facilities), Aster DM Healthcare (large primary and secondary care network), and Thumbay Group. Each has its own procurement governance, typically combining central contracts with facility level discretion for specialty and named patient supply.

Cold Chain Requirements: Heathrow to DXB

UAE summers regularly produce ambient ground temperatures above 45 degrees Celsius and have been recorded above 50 degrees in inland locations during peak summer. This makes cold chain integrity a more acute issue in the UAE than in many other markets, and MOHAP, DHA, and DOH inspectors are familiar with the nuances of validating temperature controlled shipping under high ambient conditions.

Core cold chain requirements UK exporters should meet:

• Validated temperature-controlled storage at the UK supplier location, MHRA validated, with documented qualification records.
• Qualified shipping containers validated for the Heathrow to DXB or AUH route under elevated ambient conditions. Active temperature controlled containers (such as Envirotainer or Va-Q-tec) are preferred for high value or high risk consignments. Passive containers are acceptable for lower value or shorter duration consignments where validation supports the route.
• Continuous temperature data logger covering the full UK to UAE journey, including the airline ramp, in flight cargo hold, transit at DXB or AUH, customs handling, and onward distribution to the consignee. The logger record is reviewed at port of entry and is part of the GDP audit trail.
• Stability data covering the transit profile. For most MHRA approved cold chain products, existing manufacturer stability data is sufficient. For novel modalities or complex biologics, bridging stability studies covering the elevated ambient profile may be needed.
• GDP-compliant transport network. The full chain from UK warehouse, to airline ramp at Heathrow, into DXB or AUH, through UAE customs, and onward to the consignee, must be GDP compliant. UK exporters with experience routing through DXB typically partner with UAE based GDP compliant logistics providers for the in country leg.
• Deviation handling procedure. Even with validated shipping, occasional excursions occur. A documented deviation procedure agreed with the consignee in advance, including who performs the technical assessment, what stability data supports the decision, and who has the authority to release or reject the consignment, prevents excursions becoming weeks long disputes.

Direct flights from Heathrow to DXB typically take 7 hours, with multiple daily services on Emirates, British Airways, and Virgin Atlantic. Heathrow to AUH is similar at 7 hours. Same day despatch from a Heathrow proximate UK warehouse delivers to UAE consignees within 48 to 72 hours including customs clearance.

For more on the practical mechanics of UAE cold chain, see our UK cold chain pharmaceutical supply page and the detailed pharma cold chain logistics guide.

Common Pitfalls (and How to Avoid Them)

Across UAE supply projects, several recurring pitfalls account for the bulk of timeline slippage and rejected consignments.

1. Mainland vs free zone confusion

The most frequent strategic error. Selecting full MOHAP registration when free zone movement was available, or assuming free zone rules apply when the consignment is actually entering UAE local market. Solution: clarify the destination of every batch upfront. Local consumption requires MOHAP registration. Re export through JAFZA or DAFZA does not, but does require free zone partner arrangements.

2. Out of date or incorrect format CPP

The CPP must be a current MHRA issued WHO format document, not an internal manufacturer export certificate. Plan for 4 to 8 week MHRA turnaround and confirm validity period against the intended MOHAP submission date.

3. Halal and alcohol disclosure omissions

Products containing porcine derived gelatin, bovine derived materials, or alcohol excipients must be declared. Omitting this at registration leads to deficiency cycles and delays. Disclose clearly upfront.

4. Arabic labelling errors

UAE Arabic labelling rules differ from SFDA Saudi rules. Using a single labelling pack for both markets without market specific adaptation produces label rejection. Maintain separate Saudi and UAE Arabic labelling packs.

5. Pricing reference misalignment

UAE references prices from defined countries including UK, France, Germany, and selected GCC states. Submitting UAE pricing materially out of line with reference country pricing extends review. Ensure UK manufacturer pricing data is supplied accurately as part of the dossier.

6. Cold chain temperature excursion handling

UAE summer heat increases the probability of in transit excursions. Document the deviation handling procedure in advance with the UAE consignee, including who performs the assessment and how the decision is recorded.

7. Free zone documentation gaps

JAFZA and DAFZA partnerships look administratively simple but have specific bonded warehouse, in zone movement, and re export documentation requirements. Engage a free zone licensed distribution partner with established systems rather than improvising.

8. Hospital direct supply assumptions

Direct hospital supply works for some hospitals and not others. Cleveland Clinic Abu Dhabi, Mediclinic, NMC, and American Hospital Dubai all have established procurement governance. Other facilities require approved local agents or licensed importers. Do not assume direct hospital supply applies until confirmed.

How Euro Biom Supports UAE Supply

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239, with substantial UAE supply experience. Our role focuses on the UK supply leg of UAE bound pharmaceutical export, working closely with UAE local agents, hospital procurement teams, and free zone distribution partners.

Across the UAE pathway, our typical role covers:

• UK side documentation. Coordinating MHRA Certificate of Pharmaceutical Product procurement, GMP certificate retrieval, batch release certification with the manufacturer's QP, GDP-compliant export pack including CoA, halal and alcohol disclosure, packing list, chamber-attested commercial invoice, and UAE pricing letter where applicable.
• Cold chain logistics from Heathrow. GDP-validated temperature-controlled storage, qualified shipping containers validated for UAE summer ambient conditions, calibrated data loggers, and Heathrow despatch with direct routing to DXB or AUH.
• Named patient and special import. Working with DHA, DOH, SEHA, Cleveland Clinic Abu Dhabi, Mediclinic, NMC, American Hospital Dubai, and DHCC affiliated hospitals to deliver special import authorised consignments, often within 5 working days from confirmed enquiry, and within 48 to 96 hours for urgent cases.
• Free zone re export support. Coordination with JAFZA and DAFZA-licensed distribution partners for UK consignments destined for onward GCC and Africa supply through UAE bonded warehouse routes.
• Shortage and emergency supply. Rapid response on MOHAP shortage list items where Heathrow proximity, MHRA-licensed inventory, and same day despatch capability are decisive.
• Hospital direct supply. Established documentation pack templates for the major UAE hospital networks, simplifying repeat orders once the initial supply relationship is set up.
• Tender support. Documentation packs for UAE local agents and licensed importers bidding into MOHAP, DHA, DOH, and SEHA tenders, including supply chain assurance evidence, GDP certification, lead time commitments, and pricing letters. See our tender and government supply service.

For more on the specific commercial entry points to the UAE market, see our UK pharmaceutical exporter to UAE page. For regional context, see the GCC overview. For detail on UK side compliance see the compliance page, and for service level detail the services page. For relevant adjacent reading, the Saudi Arabia and UAE import guide and the cold chain logistics guide are companion reads to this article.